Kiora Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 1.56 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 9.93M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the tre...